Eur J Heart Fail:社区慢性心力衰竭患者的生存情况

2019-09-16 xing.T MedSci原创

由此可见,这些结果可以为健康政策和个体患者的高级护理计划提供信息。尽管生存率稳步提高,但与慢性心力衰竭相关的死亡率仍然很高。通过更多的循证治疗,仍有很大程度改善预后的空间。建议进一步研究探索阻碍和促进治疗的因素。

最近,心血管领域权威杂志European Journal of Heart Failure上发表了一篇研究文章,该研究旨在为慢性心力衰竭患者提供可靠的生存估计,并通过关键因素解释生存率的变化,包括诊断年龄、左心室射血分数、诊断年数和研究设置。

研究人员检索了相关数据库,检索日期从数据库成立之日至2018年8月,主要检索报告了门诊中慢性或稳定性心力衰竭患者存活率的非干预性研究。在所纳入的60项研究中,有150万份心衰患者的生存数据。

在研究人员的随机效应荟萃分析中,1个月、1年、2年、5年和10年的合并存活率分别为95.7%(95%置信区间为94.3-96.9)、86.5%(85.4-87.6)、72.6%(67.0-76.6)、56.7%(54.0-59.4)和34.9%(24.0-46.8)。在整个医疗保健环境中,1970年至1979年和2000年至2009年间,5年生存率从29.1%(25.5-32.7)提高到59.7%(54.7-64.6)。诊断时年龄的增加与生存时间的缩短显著相关。在次级保健中进行的研究死亡率最低,其中报告的关键心力衰竭药物的处方率较高。纳入的研究在心力衰竭诊断标准、参与者合并症和治疗率方面存在显著的异质性。

由此可见,这些结果可以为健康政策和个体患者的高级护理计划提供信息。尽管生存率稳步提高,但与慢性心力衰竭相关的死亡率仍然很高。通过更多的循证治疗,仍有很大程度改善预后的空间。建议进一步研究探索阻碍和促进治疗的因素。 

原始出处:

Nicholas R. Jones.et al.Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis.European journal of heart failure. 2019.https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1594

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1251807, encodeId=d72f125180ef2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357273, encodeId=07c2135e27349, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395843, encodeId=c148139584398, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563148, encodeId=454815631483c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1251807, encodeId=d72f125180ef2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357273, encodeId=07c2135e27349, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395843, encodeId=c148139584398, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563148, encodeId=454815631483c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
    2019-09-18 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1251807, encodeId=d72f125180ef2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357273, encodeId=07c2135e27349, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395843, encodeId=c148139584398, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563148, encodeId=454815631483c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1251807, encodeId=d72f125180ef2, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357273, encodeId=07c2135e27349, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395843, encodeId=c148139584398, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563148, encodeId=454815631483c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Sep 18 11:52:00 CST 2019, time=2019-09-18, status=1, ipAttribution=)]
    2019-09-18 slcumt

相关资讯

JAHA:慢性心力衰竭患者去甲肾上腺素水平与铁状态异常之间的关系

由此可见,在慢性心力衰竭患者中,用去甲肾上腺素水平估计的交感神经活化增加与铁状态受损有关,特别是生物标志物的失调表明铁转运受损和铁需求增加。在未来的研究中,需要阐明去甲肾上腺素和铁代谢之间的关系是否是双向的,并且存在因果关系。

慢性心力衰竭:FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格

礼来和勃林格殷格翰近日表示,FDA已授予Jardiance(empagliflozin)快速通道资格用于降低慢性心力衰竭患者心血管死亡和心力衰竭住院的风险。

Int J Cardiol:慢性心力衰竭患者癌症死亡风险增加

由此可见,这些结果提供了HF与癌症死亡增加相关的第一个证据,特别是当与长期炎症相关时。

NEJM:经皮二尖瓣修补术不能改善慢性心力衰竭伴左室射血分数降低患者预后

研究认为,经皮二尖瓣修补术对慢性心力衰竭伴左室射血分数降低的患者无显著疗效

Int J Cardiol:袢利尿剂治疗对慢性心力衰竭患者死亡率的比较分析

由此可见,对于HF患者,死亡率不受个体袢利尿剂选择的影响。

新指南已出 慢性心力衰竭的治疗方法再优化

心力衰竭(简称“心衰”)是各种心脏疾病的严重表现或晚期阶段,死亡率和再住院率居高不下。流行病学调查显示,我国35~74岁成人心衰患病率为0.9%[1]。随着人口老龄化加剧,以及医疗水平的提高使心脏疾病患者生存期延长,导致我国心衰患病率呈持续升高趋势。根据近年来心衰领域的最新研究证据,参考最新欧美心衰指南,结合我国国情及临床实践,“中国心力衰竭诊断和治疗指南2018”基于2014版中国心衰指南进